Keywords (1)

Academic
Publications
Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents

Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Age

Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents   (Citations: 165)
BibTex | RIS | RefWorks Download
Journal: Journal of Clinical Endocrinology & Metabolism - J CLIN ENDOCRINOL METAB , vol. 87, no. 4, pp. 1586-1592, 2002
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...In a meta-analysis of studies that examined the relationship between change in bone turnover and incidence of non-vertebral fracture, Hochberg et al. demonstrated a reduced risk of non-vertebral fracture in those studies with a decrease in bone turnover markers >50% [27]...

    R. Eastellet al. Effects of raloxifene and alendronate on bone turnover as assessed by ...

    • ...Overall 50 (16, 70) 0.012 46 (9, 68) 0.024 47 (23, 63) 0.001 61 (32, 78) 0.001 65 (38, 81) 0.001 62 (44, 75) 0.001 70 yr of age 52 (7, 75) 0.032 22 (53, 60) 0.512 40 (5, 62) 0.037 62 (25, 81) 0.007 64 (19, 84) 0.016 62 (36, 77) 0.001 2 Prevalent vertebral fractures 51 (18, 71) 0.010 50 (12, 71) 0.018 49 (26, 65) 0.001 65 (37, 80) 0.001 74 (47, 88) 0.001 68 (51, 80) 0.001...
    • ...Meta-analyses based on summary statistics have shown that increases in BMD account for a significant portion of the reductions in fracture risk associated with antiresorptive treatment (26, 27, 33)...

    NELSON B. WATTSet al. Risedronate Prevents New Vertebral Fractures in Postmenopausal Women a...

    • ...This has been unsatisfactory because of the long delay between initiation of therapy and assessment of the effectiveness of that therapy and because changes in bone mineral density on fracture prevention therapies are only mildly correlated with fracture reduction efficacy (63,64)...

    Greg Teschet al. Successes Achieved and Challenges Ahead in Translating Biomarkers into...

    • ...Several statistical methodologies have been used, including meta-analyses based on groups of patients [4, 5] and on individual patient data [12] and the application of a surrogate marker analysis, first proposed by Freedman and colleagues [17] and applied to osteoporosis [18]...
    • ...In general, these results are similar to findings with other antiresorptives [4, 5, 8, 9] and a meta-analysis of ibandronate studies [28]...
    • ...Similar results were obtained from a later meta-analysis of 18 trials: Estimated RRRs for nonvertebral fractures were 39% for a 6% increase in lumbar spine BMD at 1 year and 46% for a 3% increase in hip BMD [5]...

    Paul D. Milleret al. Increases in Hip and Spine Bone Mineral Density are Predictive for Ver...

    • ...In a meta-analysis of fracture studies with antiresorptive agents, reductions in resorption markers of 50–60% and of formation markers of 40–50% were required to demonstrate non-vertebral fracture risk reduction [18]...

    R. W. Downs Jret al. Effects of arzoxifene on bone, lipid markers, and safety parameters in...

Sort by: